Non Small Cell Lung Cancer (NSCLC) Therapeutics Market Size, Share and Industry Analysis by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Cancer Type (Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma), and Regional Forecast 2019-2032

Last Updated: October 21, 2024 | Format: PDF | Report ID: FBI100484

Table of Content:

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4. Key Insights

4.1 Prevalence of Non Small CellLung Cancer by Type

4.2 Regulatory Scenario by KeyRegions

4.3 Key Industry Developments

4.4 Pipeline Analysis

4.5 Overview of Current Advances in R&D for Non Small Cell Lung Cancer Therapeutics

5. Global Non SmallCell Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026

5.1. Key Findings / Summary

5.2. Market Analysis, Insightsand Forecast – By Therapy

5.2.1 Targeted Therapy

5.2.1.1 Bevacizumab

5.2.1.2 Dabrafenib/Trametinib

5.2.1.3 Erlotinib Hydrochloride

5.2.1.4 Osimertinib

5.2.1.5 Others

5.2.2 Immunotherapy

5.2.2.1 Durvalumab

5.2.2.2 Nivolumab

5.2.2.3 Atezolizumab

5.2.2.4 Pembrolizumab

5.2.3 Chemotherapy

5.3. Market Analysis, Insights and Forecast – By Distribution Channel

5.3.1 Hospital Pharmacies

5.3.2 Retail Pharmacies

5.3.3 Online Pharmacies

5.3.4 Others

5.4 Market Analysis, Insights and Forecast – By Cancer Type

5.4.1 Adenocarcinoma

5.4.2 Squamous Cell Carcinoma

5.4.3 Large Cell Carcinoma

5.5. Market Analysis, Insights and Forecast – By Region

5.5.1 North America

5.5.2 Europe

5.5.3 Asia Pacific

5.5.4 Latin America

5.5.5 Middle East & Africa

6. North America Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast,2015-2026

6.1. Key Findings / Summary

6.2. Market Analysis – By Therapy

6.2.1 Targeted Therapy

6.2.1.1 Bevacizumab

6.2.1.2 Dabrafenib/Trametinib

6.2.1.3 ErlotinibHydrochloride

6.2.1.4 Osimertinib

6.2.1.5 Others

6.2.2 Immunotherapy

6.2.2.1 Durvalumab

6.2.2.2 Nivolumab

6.2.2.3 Atezolizumab

6.2.2.4 Pembrolizumab

6.2.3 Chemotherapy

6.3. Market Analysis – By Distribution Channel

6.3.1 Hospital Pharmacies

6.3.2 Retail Pharmacies

6.3.3 Online Pharmacies

6.3.4 Others

6.4. Market Analysis – By Cancer Type

6.4.1 Adenocarcinoma

6.4.2 Squamous Cell Carcinoma

6.4.3 Large Cell Carcinoma

6.5. Market Analysis – By Country

6.5.1 U.S.

6.5.2 Canada

7. Europe Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026

7.1. Key Findings / Summary

7.2. Market Analysis – By Therapy

7.2.1 Targeted Therapy

7.2.1.1 Bevacizumab

7.2.1.2 Dabrafenib/Trametinib

7.2.1.3 Erlotinib Hydrochloride

7.2.1.4 Osimertinib

7.2.1.5 Others

7.2.2 Immunotherapy

7.2.2.1 Durvalumab

7.2.2.2 Nivolumab

7.2.2.3 Atezolizumab

7.2.2.4 Pembrolizumab

7.2.3 Chemotherapy

7.3. Market Analysis – By Distribution Channel

7.3.1 Hospital Pharmacies

7.3.2 Retail Pharmacies

7.3.3 Online Pharmacies

7.3.4 Others

7.4. Market Analysis – By Cancer Type

7.4.1 Adenocarcinoma

7.4.2 Squamous Cell Carcinoma

7.4.3 Large Cell Carcinoma

7.5. Market Analysis – By Country/Sub-region

7.5.1 Germany

7.5.2 U.K.

7.5.3 France

7.5.4 Italy

7.5.5 Spain

7.5.6S candinavia

7.5.7 Rest of Europe

8. Asia Pacific Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast,2015-2026

8.1. Key Findings / Summary

8.2. Market Analysis – By Therapy

8.2.1 Targeted Therapy

8.2.1.1 Bevacizumab

8.2.1.2 Dabrafenib/Trametinib

8.2.1.3 Erlotinib Hydrochloride

8.2.1.4 Osimertinib

8.2.1.5 Others

8.2.2 Immunotherapy

8.2.2.1 Durvalumab

8.2.2.2 Nivolumab

8.2.2.3 Atezolizumab

8.2.2.4 Pembrolizumab

8.2.3 Chemotherapy

8.3. Market Analysis – By Distribution Channel

8.3.1 Hospital Pharmacies

8.3.2 Retail Pharmacies

8.3.3 Online Pharmacies

8.3.4 Others

8.4. Market Analysis – By Cancer Type

8.4.1 Adenocarcinoma

8.4.2 Squamous Cell Carcinoma

8.4.3 Large Cell Carcinoma

8.5. Market Analysis – By Country/ Sub-region

8.5.1 China

8.5.2 India

8.5.3 Japan

8.5.4 Australia

8.5.5 Southeast Asia

8.5.6 Rest of Asia Pacific

9. Latin America Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast,2015-2026

9.1. Key Findings / Summary

9.2. Market Analysis – By Therapy

9.2.1 Targeted Therapy

9.2.1.1 Bevacizumab

9.2.1.2 Dabrafenib/Trametinib

9.2.1.3 Erlotinib Hydrochloride

9.2.1.4 Osimertinib

9.2.1.5 Others

9.2.2 Immunotherapy

9.2.2.1 Durvalumab

9.2.2.2 Nivolumab

9.2.2.3 Atezolizumab

9.2.2.4 Pembrolizumab

9.2.3 Chemotherapy

9.3. Market Analysis – By Distribution Channel

9.3.1 Hospital Pharmacies

9.3.2 Retail Pharmacies

9.3.3 Online Pharmacies

9.3.4 Others

9.4. Market Analysis – By Cancer Type

9.4.1 Adenocarcinoma

9.4.2 Squamous Cell Carcinoma

9.4.3 Large Cell Carcinoma

9.5. Market Analysis – By Country/ Sub-Region

9.5.1 Brazil

9.5.2 Mexico

9.5.3 Rest of Latin America

10. Middle East &Africa Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026

10.1. Key Findings / Summary

10.2. Market Analysis – By Therapy

10.2.1 Targeted Therapy

10.2.1.1 Bevacizumab

10.2.1.2 Dabrafenib/Trametinib

10.2.1.3 Erlotinib Hydrochloride

10.2.1.4 Osimertinib

10.2.1.5 Others

10.2.2 Immunotherapy

10.2.2.1 Durvalumab

10.2.2.2 Nivolumab

10.2.2.3 Atezolizumab

10.2.2.4 Pembrolizumab

10.2.3 Chemotherapy

10.3. Market Analysis – By Distribution Channel

10.3.1 Hospital Pharmacies

10.3.2 Retail Pharmacies

10.3.3 Online Pharmacies

10.3.4 Others

10.4. Market Analysis – By Cancer Type

10.4.1 Adenocarcinoma

10.4.2 Squamous Cell Carcinoma

10.4.3 LargeCell Carcinoma

10.5. Market Analysis – By Country/ Sub-region

10.5.1 South Africa

10.5.2 GCC Countries

10.5.3 Rest of Middle East & Africa

11. Competitive Analysis

11.1. Key Industry Developments

11.2. Global Market Share Analysis (2018)

11.3. Competition Dashboard

11.4. Comparative Analysis –Major Players

11.5. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability))

11.5.1 Genentech, Inc. (F. Hoffmann-La Roche Ltd)

11.5.2 EliLilly and Company

11.5.3 CelgeneCorporation

11.5.4 AstraZeneca

11.5.5 PfizerInc.

11.5.6 Sanofi

11.5.7 Novartis AG

11.5.8 Astellas Pharma Inc.

11.5.9 Bristol-Myers Squibb Company

11.5.10 Boehringer Ingelheim Pharmaceuticals, Inc.

11.5.11 Millennium Pharmaceuticals, Inc. (Takeda)

11.5.12 Merck Sharp & Dohme Corp.

11.5.13 Other Prominent Players

12. Strategic Recommendations

REPORT UPDATE
IN PROCESS
STUDY PERIOD: 2019-2032
(In Process)
BASE YEAR:2023
(In Process)

Healthcare Clients

Related Reports

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry

Get in Touch with Us

+1 424 253 0390 (US)
+44 2071 939123 (UK)
+91 744 740 1245 (APAC)
[email protected]